Weight Loss Peptides Retatrutide, Cagrilintide, CagriSema Dosing Overview: 

The following is NOT MEDICAL Advice, this is for information purposes only.
Always consult your physician before making any changes to your medical plan.
Peptides purchased direct online are sold “for research purposes only”
Project Biohacked LLC

Solution Peptides carries all of the following peptides and I am getting quite a few questions on them so I decided to do a little overview on dosing from the ongoing human clinical trials.

• The following information is in part overview of dosages used in human clinical trials and part my personal opinion on POTENTIAL dosing approaches for these RESEARCH PEPTIDES.
• I will be gathering more community feedback on these newer GLP1 Peptides from the community in coming weeks and reporting my findings!!

• My research approach is ALWAYS for very first dose I consider it a TEST dose and I reduce the dose by ½ to ¼ the “suggested starting dose” based on the human studies.
• This significantly reduces risk of side effects, allows research animal to gauge tolerance and may result in research subject finding a much lower dose is all thats needed!!
• I have utilized and taught this simple principle for 7+ YEARS now with peptides and other compounds. It is a simple approach that can be applied to ALL peptides.
• As always remember there is no one size fits all approach so FIND what works best for your research utilizing the LOW and SLOW Biohacking principle 🙂

Retatrutide (LY3437943) is an triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.

https://pubmed.ncbi.nlm.nih.gov/37385280/

• Dosages used in clinical trials ranged from 1mg 1x per week up to 12mg 1x per week

• I like a very conservative TEST dose for week 1 at 1/2 – 1/4 the lowest dose studied
• Reason being MANY individuals have reported strong side effects at the starting dose recommended for Semaglutide and or Tirzepatide.
• We have found that research subjects who cut dose by 1/2 – 1/4 starting out SIGNIFICANTLY reduce side effects. We have also learned that some subjects will actually lose weight at those reduced doses.
• This approach ALWAYS helps to mitigate side effects with ALL PEPTIDES. It’s a universal approach that can be used.

Ex. 1/2 the “suggested” starting dose of 1mg would be .5mg (500mcg)

Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management.

• Dosing used in most recent human clinical trials ranged from .3mg up to 4.5mg at a dosing frequency of 1x per week
• https://www.semanticscholar.org/paper/Once-weekly-cagrilintide-for-weight-management-in-a-Lau-Erichsen/7eec2610e06b95d47695205d4eaa741f4502a65b

• ANY new peptide/compound I personally like to start w/ a test dose for the research subject. I typically like to go 1/2 to sometimes even 1/4 the “suggested starting dose”. This helps to mitigate subject side effects as well as give the subjects body time to adjust to the peptide.
• Based on that first dose response I will then slowly titrate up towards doses that have been found efficacious in the literature.
• So in this situation my approach would be a test dose for week 1 at approximately .15mg (150mcg)
• This would be 1/2 the lowest dose studied that showed efficacy for weight loss
• For subjects who tend to be EXTREMELY sensitive I would consider a test dose of 1/4 the lowest dose studied.
• This test does is NOT to try and lose weight that first week but to gauge tolerance/ avoid side effects. Then taper up based on response.
• (NOT MEDICAL Advice this is for information purposes only)
• Project Biohacked LLC

Ex. 1/2 the “suggested” starting dose of .3mg would be .15mg (150mcg)

“The results indicate that CagriSema reduces blood sugar more than semaglutide alone, and the weight loss seen in the trial confirms the substantial weight lowering potential of CagriSema.”

• Dosing in Cagri Sema studies ranged .16mg Cagri up to 4.5mg Cagri
• Combined with Semaglutide at 2.4mg (THAT’S MAX SEMA DOSE!!)
• A separate study SLOWLY titrated subjects to 2.4mg of Cagri and 2.4mg of Sema
• Again important to know 2.4mg of Sema is MAX STUDIED dose and would absolutely ROCK some subjects with side effects..
• https://pubmed.ncbi.nlm.nih.gov/33894838/

• My personal opinion on researching CagriSema would be a very conservative test dose at .15mg (150mcg) of Cagri and .15mg (150mcg) of Sema
• It appears at around 1.2mg of Cagri close to peak benefits were achieved but there is NEVER a one size fits all approach. Subjects may notice benefits at a lower dose, personally I do not like to rush tapering up if subject is having benefits at lower doses.
• Same ole principles I preach 🙂 START LOW and SLOW then SLOWLY TAPER UP and back off – slow titration if needed.
• This approach ALWAYS helps to mitigate side effects with ALL PEPTIDES. It’s a universal approach that can be used.

I will be gathering real world feedback on these peptides in coming weeks so look out for those findings!!